Research Study Summary
A Phase 3, Randomized, Double-Blind Study Comparing ABT-494 to Placebo on Stable Conventional Synthetic Disease-Modifying Anti-Rheumatic Drugs (csDMARDs) in Subjects with Moderately to Severely Active Rheumatoid Arthritis with Inadequate Response or Intolerance to Biologic DMARDs (bDMARDs)
Rheumatoid arthritis (RA) is a chronic systemic inflammatory disease of unknown etiology. The hallmark feature of RA is an inflammatory process manifested by persistent symmetric polyarthritis of synovial joints which can ultimately lead to bone erosions,
deformity, and disability. Early therapy with disease-modifying anti-rheumatic drugs (DMARDs) is the standard of care. Despite major progress in the treatment of RA, there still remains a large unmet medical need and novel therapies are needed to complement the available interventions to address this unmet need.
To Learn more
CW ID: 216048
Date Last Changed:
June 14, 2016
Clinical Trial Snapshot
- Both Male and Female
- 18 and up
- Overall Status
- Facility Type
- Diagnosis of RA for ≥ 3 months who also fulfill either the 1987-revised ACR classification criteria
or the 2010 ACR/EULAR classification criteria for RA.
- Subjects have been treated for ≥ 3 months with ≥ 1 bDMARD therapy, but continue to exhibit active RA or had to discontinue due to intolerability or toxicity.
- Subjects have been receiving csDMARD therapy ≥ 3 months and on a stable dose for ≥ 4 weeks prior
to the first dose of study drug.
- Prior exposure to any Janus kinase (JAK) inhibitor.
- History of inflammatory joint disease other than RA
DISCLAIMER: CenterWatch does not conduct clinical research.
CenterWatch is a publishing company that posts clinical trials information on behalf of sponsor companies,
contract research organizations, clinical research sites and other interested parties. This information
is designed to help patients find clinical trials of interest and contact the research centers
conducting the trials.